These data support our hypothesis that AKR1C1-3 enzymes could modulate drug sensitivity in T-ALL cells as demonstrated by a clear-cut overexpression and activation in MRDpos T-ALL patients. The gene discussed is AKR1C1; the disease is acute lymphoblastic leukemia.